(Q45396135)

English

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies

scientific article published on 13 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Terrence M Tumpey

7

object named as

Terrence M Tumpey

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

6

object named as

Wing-Pui Kong

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

5

object named as

Claudia Pappas

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Chia-Yun Lo

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Zhengqi Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Julia A Misplon

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Graeme E Price

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Suzanne L Epstein

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

13 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2062-2072

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Control of influenza virus infection by immunity to conserved viral features.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Evaluation of live and inactivated influenza A virus vaccines in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Pulmonary CD4+ cytokine responses in mice reveal differences in the relative immunogenicity of cold-adapted influenza A vaccine donor strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Modified M2 proteins produce heterotypic immunity against influenza A virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Origin and evolution of influenza virus hemagglutinin genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Development of stable liquid formulations for adenovirus-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Development of formulations that enhance physical stability of viral vectors for gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Persistent host markers in pandemic and H5N1 influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

based on heuristic

inferred from DOI database lookup

Humoral and cellular responses of mice to infection with a cold-adapted influenza A virus variant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

based on heuristic

inferred from DOI database lookup

The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.047

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.02.047

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45396135&oldid=2076551444"